Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Buy Back as Much as $10M of Its Stock Over Four Years

NEW YORK (GenomeWeb News) — PerkinElmer on Monday said it plans to buy back as much as 10 million shares of its common stock over the next four years.

PerkinElmer’s board authorized the buyback, which will be made over the open market or “through privately negotiated transactions,” the company said.

Two weeks ago, PerkinElmer reported that third-quarter revenues rose 7 percent as profirs slid 7 percent.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.